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Abstract
The cystic fibrosis transmembrane conductance regulator (CFTR) gene was identified in 1989. This opened the
door for the development of cystic fibrosis (CF) gene therapy, which has been actively pursued for the last 20
years. Although 26 clinical trials involving approximately 450 patients have been carried out, the vast majority
of these trials were short and included small numbers of patients; they were not designed to assess clinical
benefit, but to establish safety and proof-of-concept for gene transfer using molecular end points such as the
detection of recombinant mRNA or correction of the ion transport defect. The only currently published trial
designed and powered to assess clinical efficacy (defined as improvement in lung function) administered
AAV2-CFTR to the lungs of patients with CF. The U.K. Cystic Fibrosis Gene Therapy Consortium completed,
in the autumn of 2014, the first nonviral gene therapy trial designed to answer whether repeated nonviral gene
transfer (12 doses over 12 months) can lead to clinical benefit. The demonstration that the molecular defect in
CFTR can be corrected with small-molecule drugs, and the success of gene therapy in other monogenic
diseases, is boosting interest in CF gene therapy. Developments are discussed here.
Cystic Fibrosis: An Introduction to the Disease
Cystic fibrosis (CF) is an autosomal recessive diseasecaused by mutations in the cystic fibrosis transmem-
brane conductance regulator (CFTR) gene. The CFTR gene
encodes a protein that has several functions including cAMP-
dependent chloride and bicarbonate secretion and regulation
of epithelial sodium channels (ENaCs). CFTR is, therefore,
important in the regulation of ion and fluid homeostasis
across epithelial barriers.1
The CFTR gene is expressed in the epithelium of many
organs including the lungs, kidney, the gastrointestinal and
reproductive tracts, liver, and pancreas leading to multiorgan
disease.2 In the developed world progressive pulmonary dis-
ease causes most morbidity and mortality. The respiratory
disease is characterized by persistent cycles of lung infection
and inflammation leading to mucous obstruction of the air-
ways. Although the role of CFTR in transepithelial ion trans-
port and host defense is widely accepted, there is ongoing
debate about some of the key processes. The ‘‘low volume’’
hypothesis,3 which postulates that decreased transepithelial
chloride transport, due to mutated CFTR, and increased
transepithelial sodium absorption, due to lack of CFTR-de-
pendent inhibition of ENaCs, lead to increased water absorp-
tion into the tissue and, therefore, decreased airway surface
liquid and reduced mucociliary clearance has long been the
leading hypothesis. This hypothesis is consistent with altered
potential difference measurements in the nose and upper air-
ways of patients with CF.4,5 Studies in the CF knockout pig
confirmed the lack of chloride transport and sodium hyper-
absorption in nasal epithelium,6 but highlighted that sodium
hyperabsorption and depletion of airway surface liquid were
not present in CF pig lower airways,7 thereby somewhat
questioning the validity of the ‘‘low volume’’ hypothesis.
However, consistent with patients with CF, the CF pig also had
reduced CFTR-dependent bicarbonate secretion in the air-
ways,7 which in the pig leads to reduced airway surface pH
causing impairment of innate bacterial defense mechanisms.8
The role of CFTR expression in inflammatory cells such as
neutrophils, macrophages, and more recently T cells, has been
widely, and so far, inconclusively debated,9–13 but studies
overall appear to suggest a potential defect in adaptive immune
responses in patients with CF, which may explain the exag-
gerated pulmonary inflammatory responses that have been
generally observed, an area that requires further studies.
CF is the most common genetic disease in the white
population. Approximately 80,000 people have been diag-
nosed with CF in the United States and Europe14 with
10,000 patients with CF living in the United Kingdom to-
day, of which more than 57% are adults.15 However, in-
creasing numbers of patients with CF are being identified in
other large populations including China and India. CF was
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first defined as a disease in 1938, but the CFTR gene was not
identified until 198916–18; a landmark that opened the door
for the development of CF gene therapy. To date more than
1990 mutations have been identified within the CFTR gene,19
but not all can be conclusively categorized as disease-causing.
On the basis of the resulting cellular phenotype the muta-
tions can be classified into six classes2 (Table 1). Classes I–
III tend to abolish CFTR expression and/or function (severe
mutations) whereas classes IV–VI produce CFTR variants
with residual expression and/or function (mild mutations).2
Although the genotype–phenotype correlation is strong for
pancreatic disease (severe mutations lead to pancreatic in-
sufficiency and patients require enzyme supplements to di-
gest food, whereas patients with mild mutations remain
pancreatically sufficient), in the lung the environment, so-
cioeconomic factors, and other modifier genes significantly
contribute to disease severity. By far the most common mu-
tation worldwide is a deletion of phenylalanine (Phe508del,
previously called DF508). In the United Kingdom 90% of
patients with CF are homozygous or compound heterozygous
for Phe508del, although the absolute frequency varies among
different populations. Several therapies including, among
others, inhaled antibiotics, macrolides, and novel mucolytics
such as dornase alfa (a recombinant DNase) and hypertonic
saline, have progressed from clinical trials into mainstream
treatment and led to a steady increase in median predicted
survival, which is currently 37 years in the United Kingdom.15
The introduction of clinical trial networks in the United
States20 and Europe21 has significantly contributed to the rapid
progression from bench to bedside.
Gene Therapy to Treat CF Lung Disease
As mentioned previously, the cloning of the CFTR gene
was a landmark for the development of CF gene therapy.
The vast majority of efforts over the last 20 years have
focused on developing gene therapy for CF lung disease,
largely due to the urgent need for more effective treatments
and the noninvasive accessibility of the lung.
Identification of the now-licensed CFTR potentiator Ka-
lydeco (also known as ivacaftor or VX-770) has been a
success story for high-throughput small-molecule drug de-
velopment. Kalydeco potentiates CFTR protein function in
patients with class III gating mutations.22,23 However, it is
important to note that only *4% of patients with CF carry
mutations that respond to Kalydeco. The development of
small-molecule drugs that improve CFTR processing (cor-
rectors) in patients with Phe508del mutations, which would
be beneficial for the vast majority of patients with CF, has so
far proven more difficult (reviewed in Bell et al.24). How-
ever, research into CFTR correctors and, more importantly
the potentiator Kalydeco, has shown that the molecular
defect of CFTR is drug targetable and that amelioration of
CFTR function translates into improvements in disease
phenotype. These findings have renewed interest and in-
vestment into other therapies aimed at targeting the mo-
lecular defect, including gene therapy.
Gene therapy for CF has a number of important features
compared with other experimental and established drugs:
1. In contrast to the mutation class–specific treatments de-
scribed previously, gene therapy is mutation class inde-
pendent and will likely be suitable for all patients.
2. In contrast to many other established drugs, gene therapy
will target the disease at its origin, the molecular defect.
This offers the potential for lung disease prevention, if
treatments are initiated early.
3. As described previously, disease pathophysiology is
widely debated. Lung gene therapy will not require dis-
ease pathology to be completely illuminated. However, if
CFTR expression in inflammatory cells turns out to be an
important factor for host defense, additional gene therapy–
based strategies such as transduction of bone marrow–
derived cells may be important.
Challenges for CF Gene Therapy
The development of pulmonary gene therapy has been
slower than initially predicted and hoped for. The lung is a
complex and difficult target organ because of the presence
of potent intra- and extracellular barriers that have evolved
to protect the lungs from foreign bodies including bacteria,
viruses, and gene transfer agents. Extracellular mucus and
CF sputum, cilia beating, and the nuclear membrane all
affect the efficiency of gene transfer.25 In addition, a number
of other questions are currently unresolved.
What level of CFTR gene expression is required
to achieve clinical benefit in the treated patient?
A body of evidence suggests that even modest amounts of
CFTR expression may suffice to improve lung disease.
First, data from early in vitro studies suggest that low-
level correction of 6–10% of CFTR gene expression in
airway epithelium can restore chloride transport to non-CF
levels.26 However, later studies indicated that higher num-
bers of CFTR-expressing cells (> 25%) are necessary to
allow efficient mucous transport of CFTR.27 More recently,
adenovirus-mediated CFTR gene transfer into 20–30% of
sinus epithelial cells extracted from CF knockout pigs cor-
rected chloride transport to 50% of non-CF levels, and even
low levels of gene transfer (*7%) produced detectable
levels of correction (*6% of non-CF).28
Second, individuals with CF with certain ‘‘mild’’ muta-
tions that retain as little as 10% of normal CFTR expression
per cell generally do not suffer from lung disease, although
other organs such as the vas deferens may be affected.29
However, it is currently unclear whether low-level expres-
sion in many cells (as in patients with 10% of residual CFTR
Table 1. CFTR Gene Mutation Classes
Class Effect on protein
Key example of
disease-causing
mutations
I Defective protein production G542X
II Defective protein processing F508del
III Defective protein regulation G551D
IV Defective protein conductance R117H
V Reduced protein synthesis A455E
VI Reduced protein
surface retention
c.120del23
CFTR, cystic fibrosis transmembrane conductance regulator gene.
Of note: a large number of known CFTR mutations are currently
unclassified with respect to mutation class.
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expression) or a low number of cells expressing high levels of
CFTR (as in the cell-mixing experiments) will be required to
achieve clinical benefit after gene therapy. This question is
further complicated by the fact that molecular assays to
quantify mRNA and protein expression do not work particu-
larly well on bronchial brushings and biopsies obtained from
the lungs of patients with CF after gene transfer,30,31 due to (1)
the small amount of sample that can be obtained, (2) the region
that bronchial brushings and biopsies can be obtained from
(comparatively large third- to fourth-generation airways, ra-
ther than smaller airways in which disease first manifests), (3)
the poor specificity of anti-CFTR-specific antibodies, and (4)
the relative sensitivity of the assays.
In addition, it is unclear which of the features related to
CF pathophysiology are most important. None of the gene
therapy trials reported so far has shown evidence for cor-
rection of the sodium transport defect, and in vitro cell-
mixing experiments implied that the correction of sodium
hyperabsorption requires high numbers (close to 100%) of
non-CF cells.32,33 We are currently not aware of studies that
have addressed how much CFTR expression in how many
cells may be required to correct the bicarbonate transport
defect and associated alterations in mucus unfolding34 and
airway surface liquid pH.8
Another question that remains unresolved concerns which
cells in the lung are the most appropriate target for gene
transfer. CFTR is expressed in various lung regions and cell
types,35–39 and in our view airway epithelial cells (Fig. 1) are
currently the most likely target cell for gene replacement.
Twenty-six clinical trials involving approximately 450
patients have been carried out.40 A phrase similar to ‘‘CF
gene therapy has failed to demonstrate clinical benefit,’’
which is frequently stated in the literature, requires some
clarification. The vast majority of the CF gene therapy trials
were short and included small numbers of patients and were
not designed to assess clinical benefit, but to establish safety
and proof-of-concept for gene transfer using molecular end
points such as the detection of recombinant mRNA or cor-
rection of the ion transport defect. Early trials focused on de-
livery of gene transfer agents to the nasal epithelium, used as a
surrogate for lung delivery because of their similarity in cell
composition and being potentially safer for first-in-human
studies. Importantly, these studies clarified the strength and
weaknesses of viral and nonviral gene transfer for chronic
diseases such as CF and highlighted that preclinical models do
not well predict clinical trial outcomes. Landmark preclinical
and clinical studies are described below.
Viral Vector–Mediated Gene Transfer
Early studies: Adenoviral vectors
for CF gene therapy
Adenoviruses are nonenveloped, double-stranded DNA
viruses composed of a complex icosahedral capsid.41,42 The
knob domain of the fiber binds to the coxsackie and adeno-
virus receptor (CAR) on the cell surface and facilitates virus
entry,41,43 although integrin receptors such as avb3 and avb5
and the major histocompatibility complex (MHC) class I may
also play a role in virion–cell interaction.43 After entry the
virus remains in an episomal state within the nucleus.
Because of a natural tropism for the lung and a large
packaging capacity, adenoviral vectors were the first to be
assessed for CF gene therapy. In first-generation vectors the
E1 region was deleted to prevent virus replication. More
advanced versions, so-called helper-dependent adenoviral
(HDAd) vectors, were depleted of all viral coding se-
quences.40,44 The first, albeit not placebo-controlled, CF
gene therapy trial was reported by Zabner and colleagues in
1993, only 4 years after cloning the CFTR gene. A serotype
2 adenoviral (Ad2) vector carrying the human CFTR cDNA
was administrated to the nasal epithelium of three patients
with CF. Although patient numbers were low, this study pro-
vided the first proof-of-concept for correction of the chloride
transport defect and stimulated further interest in the devel-
opment of adenovirus-based clinical trials.45 Since 1994, nine
further adenoviral vector trials were conducted.46–54 Com-
bined, these studies showed that adenoviral vectors were not
suitable for CF gene therapy because of (1) inefficient and
transient gene transfer and (2) induction of immune responses
that prevented efficacy on repeat administration (as reviewed
in Griesenbach and Alton40).
Numerous preclinical studies have been conducted to
increase gene transfer and reduce induction of immune re-
sponses. The realization that the CAR receptors are located
on the basolateral rather than the apical membrane of airway
epithelial cells led to assessment of tight junction openers
such as sodium caprate55 and lysophosphatidylcholines,56
which showed moderate success. In addition, various im-
munosuppressive strategies were assessed, but the suitability
of tight junction openers and immunosuppression in the
context of bacteria-infected CF lungs was never addressed
systematically. The more recent development of HDAd
vectors goes somewhat toward reducing inflammatory and
immune responses,57–59 but progress has not been sufficient
to warrant assessment of HDAd vectors in CF, a chronic
disease that requires life-long gene expression.
FIG. 1. Ciliated human airway epithelial cells: target cells
for CF gene therapy. The dense ciliary border on airway
epithelial cells is a significant extracellular barrier to CF
gene therapy. Cilia are stained with an anti-tubulin-b anti-
body (green). Nuclei are stained with DAPI (blue). Picture
courtesy of M. Wasowicz (Department of Gene Therapy,
Imperial College, London). Color images available online at
www.liebertpub.com/hum
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Are AAV vectors more suitable for CF gene therapy?
The other family of viruses developed for CF gene therapy
are the adeno-associated viruses (AAVs), small nonenveloped,
single-stranded DNA viruses, which also have a natural tro-
pism for the lung and are nonpathogenic. The virus enters cells
by binding to cell surface proteoglycans (sialic acid, galactose,
or heparan sulfate)60 and to cell surface receptors such as fi-
broblast growth factor receptor or integrins.61 Although the
wild-type virus integrates into the human genome, it has been
suggested that the majority of AAV vectors remain in an
episomal nuclear configuration after conversion from single-
stranded into double-stranded DNA.62,63 However, Kaeppel
and colleagues assessed the integration site profile in patients
treated intramuscularly with alipogene tiparvovec (Glybera, an
AAV vector carrying lipoprotein lipase) and showed that in-
tegration occurred but was random and, in contrast to gamma-
retroviral vectors, which have been associated with cases of
insertional mutagenesis, not associated with preferential inte-
gration close to transcription start sites.64 Kaeppel and col-
leagues also noticed significant integration into mitochondrial
genomes, which was surprising, and raises further questions
related to AAV biology. One of the most attractive features of
AAV vectors is their ability to support prolonged gene ex-
pression in many tissues.
The first AAV CF trial was published in 1998 and over a
period of 8 years, six other clinical trials focused on deliv-
ering the vector by bronchoscope or by aerosol into nose,
lung, or sinuses were conducted. These trials were led mainly
by Targeted Genetics (now AmpliPhi Biosciences) and used
serotype 2 (AAV2).65 Initial single-dose phase I trials dem-
onstrated that virus administration to the CF airways was
safe, but provided little opportunity to assess the efficiency of
vector-specific CFTR expression. A large repeat-administra-
tion study (100 subjects), sufficiently powered to detect
changes in lung function, did not meet its primary efficacy
end point (improvement in lung function).65
There may be several reasons for these disappointing
results: (1) AAV2 is too inefficient in transducing airway
epithelial cells via the apical membrane; (2) the inverted
terminal repeat (ITR) promoter, which was used to drive
expression of the 4.7-kb CFTR cDNA because of the limited
packaging capacity (about 5 kb) of the virus, had previ-
ously been shown to support CFTR expression when used
in vitro,66 but is too weak in vivo; and/or (3) repeat ad-
ministration of AAV2 to the lung is not possible because of
the development of an antiviral immune response. No ad-
ditional AAV lung trials have been performed since 2005,
but research aimed at addressing and improving these po-
tential limitations of AAV has been actively pursued (re-
viewed in Griesenbach and Alton40; and see below for
discussion of some of the more recent studies) and some
progress, particularly related to improving transduction
efficiency, has been made.
However, on balance we would argue that AAV vectors
may face similar problems with repeat administrations as
adenoviral vectors, but a clinical trial assessing repeat ad-
ministration of an AAV vector, proven to transduce the
human airway epithelium efficiently, is the only way to
address this question reliably. Interestingly, Liu and col-
leagues have shown that AAV vectors may be able to
transduce progenitor cells in the mouse lung,67 which if
efficient may help to overcome the repeat administration
problem. In addition, Faust and colleagues have shown that
depletion of CpG dinucleotides from the AAV vector re-
duces activation of Toll-like receptor 9 (TLR9)-mediated
adaptive immune responses after intramuscular injection of
the vector, leading to reduced inflammation and prolonged
gene expression.68 However, it remains to be assessed
whether CpG-depleted AAV vectors offer any advantages
for CF gene therapy.
Several other AAV isoforms, either naturally occurring
(e.g., AAV1, AAV5, and AAV6) or generated through rational
design or directed evolution (e.g., AAV6.2), have been as-
sessed in the lung and some have been shown to lead to higher
transduction efficiency than the initial AAV2 vector.69–73
However, cross-species variation in vector transduction ef-
ficiency remains a challenging problem when deciding on
the most appropriate in vitro or in vivo model system.74
As mentioned previously, the size of CFTR (*4.7 kb) is
close to the maximal packaging capacity of the virus,75
which leaves insufficient space for potent promoters and
enhancers. Strategies based on using two AAV vectors as
carriers for the transcription cassette (trans-splicing), which
on cell entry recombine and generate a functional product,
have been proposed. Trans-splicing-based AAV-CFTR
transduction has led to partial correction of chloride trans-
port in vitro,70,76 although significant questions related to
the efficacy of this approach remain and translation into
clinical trials has not yet been proposed. Yan and colleagues
reported the generations of a chimeric virus consisting of a
human bocavirus virus-1 (HBoV1) capsid, which comfort-
ably accommodated an AAV2 genome carrying CFTR and
patented transcriptional regulatory elements.77 The chimeric
rAAV2/HBoV1 vector transduced polarized airway epithe-
lial cells more efficiently than AAV1 and AAV2 in vitro and
corrected CFTR-dependent chloride transport in vitro. It
remains to be seen whether this vector configuration holds
promise for in vivo applications.
Additional factors that may limit the efficacy of AAV
vectors in CF lungs are the sputum and bacteria-induced in-
flammation. This is further supported by studies showing that
CF sputum significantly restricts diffusion of AAV, which can
in part by overcome by reducing AAV binding to the sputum
and by decreasing sputum viscosity.78 In addition, Myint and
colleagues used several bacteria-infection models to highlight
that ongoing and recently resolved respiratory infections sig-
nificantly decrease the efficacy of AAV-mediated gene trans-
fer,79 which is relevant considering that the vast majority of
patients with CF will suffer from pulmonary infections.
Although previously we have highlighted several limita-
tions for using AAV vectors in the context of CF gene therapy,
significant advances in vector development to overcome issues
related to preexisting and adaptive immune responses and the
limited packaging capacity have been made. Importantly,
AAV vectors have proven clinical efficacy in the context of
treating hemophilia80 and Leber’s congenital amaurosis,81 and
significant investments into the vector platform have been
made by Pfizer82 and Sanofi-Genzyme.83
Do RNA Viruses Hold Promise for CF Gene Therapy?
Paramyxoviruses such as human parainfluenza virus
(hPIV) and murine Sendai virus (SeV) have been shown to
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transduce airway epithelial cells efficiently.84 Key factors
for entry of both viruses into cells are the fusion (F) and
hemagglutinin neuraminidase (HN) envelope proteins. The
HN protein mediates virus–host cell attachment via sialic
acid receptors, and the F protein is essential in fusing virus
and cell membranes, allowing the viral nucleocapsid to be
released into the host cell.85 hPIV achieved correction of the
CF-related mucus transport defect in vitro,27 but only SeV
was assessed in vivo and shown to partially correct CFTR-
dependent chloride transport in CF knockout mice.86 However,
SeV-mediated gene expression was transient (*1 week) and
the vector also induced strong adaptive immune responses that
prevented efficient repeat administration of the vector.87,88
Lentiviral vectors have shown clinical efficacy in patients
with Wiskott-Aldrich syndrome89 and metachromatic leu-
kodystrophy.90 In addition, a trial in patients with Parkin-
son’s disease demonstrated long-term safety and tolerability
of direct injection of the vector into the brain.91 Lentiviruses
are enveloped RNA viruses that belong to the family Ret-
roviridae, and in contrast to gammaretroviruses, transduce
dividing and nondividing cells,92 which make them a suit-
able vector for transduction of terminally differentiated cells
in the airways.
Human (HIV),93 simian (SIV),94 and feline (FIV) im-
munodeficiency virus,95 as well as equine infectious anemia
virus (EIAV) vector platforms,96 are being developed for CF
gene therapy. These vectors do not have a natural tropism
for the lung and therefore require pseudotyping with suitable
envelope proteins to achieve efficient transduction. The
vesicular stomatitis virus G (VSVG) protein, which is
widely used, does not transduce airway epithelium effi-
ciently via the apical membrane, but transduction efficiency
can be increased by preadministration of tight junction
openers that allow access of the virus to the basolateral
membrane.97 However, it is currently unknown whether
opening of tight junctions in the bacteria-infected CF lung is
safe. Several other groups, including our own, have used
lentiviral vectors pseudotyped with other envelope proteins
such as influenza hemagglutinin (HA)96 and glycoprotein
gp64 from baculovirus.98 We assessed an SIV vector
pseudotyped with the F and HN proteins from SeV (rSIV.F/
HN)94 and showed that the vector transduces airway epi-
thelial cells efficiently and that a single dose achieved sus-
tained gene expression for the lifetime of the mouse.99,100 It
is currently unclear whether the sustained expression was
due to a long half-life of airway epithelial cells and/or
progenitor cell integration. Surprisingly, but consistent with
data published by Sinn and colleagues,95 we also showed
that the vector can be repeatedly administered without loss
of efficacy,99,100 implying that lentiviral vectors are more
effective in escaping adaptive immune response mecha-
nisms than adenoviral and AAV vectors. These unique
features make lentiviral vectors attractive candidates for
further progression into CF gene therapy trials.
Further Steps Taken to Progress Lentiviral Vectors
Toward Clinical Trials in Patients with CF
1. Sinn and colleagues have shown that gp64-pseudotyped
lentivirus transduced porcine airways in vivo, a first step
toward assessing the efficacy of lentivirus-mediated gene
transfer in CF knockout pigs.101
2. The U.K. Cystic Fibrosis Gene Therapy Consortium
(CFGTC) has generated pharmacopoeia-compliant pro-
ducer plasmids and developed scalable GMP-compliant
production methods (CFGTC manuscript in preparation).
We have conducted an extensive study to select the most
appropriate and safest vector configuration for progression
into clinical trial (CFGTC manuscript in preparation).
3. Insertional mutagenesis due to vector integration into
the genomic DNA and possible activation of a proto-
oncogene is a recognized safety concern for gammare-
troviral vectors.102 It is important to note, however, that
lentiviral vectors have not been associated with any seri-
ous adverse events resulting from insertional mutagenesis
when used for bone marrow transduction in patients with
metachromatic leukodystrophy and Wiskott-Aldrich syn-
drome.89,90 This appears to be due to improved vector
design and differences in insertion site profiles between
gammaretroviral and lentiviral vectors.102 However, in a
b-thalassemia trial, lentiviral vector integration caused
transcriptional activation of HMGA2 in erythroid cells,
leading to clonal dominance, which to date remains be-
nign.103 Reports assessing the risk of insertional muta-
genesis of lentiviral vectors in organs other than the bone
marrow are limited. We, and others, have not seen any
evidence of insertional mutagenesis after topical admin-
istration of lentiviral vectors to the intact airways,95,100 but
extensive regulatory-compliant toxicology studies asses-
sing acute and chronic toxicity as well as integration site
profiling must be performed before progression to clinical
trials.
The U.K. CFGTC is currently working toward a first-
in-human phase I lentivirus CF gene therapy trial.
Are Nonviral Gene Transfer Agents a Suitable
Alternative to Viral Vectors for CF Gene Therapy?
Nonviral gene transfer formulations have two compo-
nents: (1) the nucleic acid, that is, the therapeutic cDNA and
appropriate regulatory elements; and (2) a carrier molecule
that binds to the DNA. In the context of CF gene therapy a
large number of carrier molecules have been developed that
may be broadly characterized as either cationic lipids or
cationic polymers. In preclinical airway in vitro and in vivo
models nonviral vectors are generally less efficient than
viral vectors,40 but a direct comparison in human lung has
not yet been carried out.
The United Kingdom has been the center of activity for
nonviral CF gene therapy. Caplen and colleagues con-
ducted the first nonviral CF nose trial in 1995,104 and be-
tween 1995 and 2004 an additional six nonviral nose gene
transfer studies (three in the United Kingdom) have taken
place,105–110 all but one using cationic lipid formu-
lations.111 In a further U.K. study in 2000, Hyde and
colleagues established proof-of-concept that repeat ad-
ministration (three doses) of a cationic liposome com-
plexed to a plasmid carrying the human CFTR cDNA
(pCFTR) to the nasal epithelium of patients with CF was
feasible without loss of efficacy.31 Alton and colleagues,
for the first time, administered the cationic lipid formula-
tion GL67A complexed to pCFTR to the lungs of U.K.
patients with CF and, encouragingly, electrophysiological
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changes could also be demonstrated in the lower airways.
The study also showed that in contrast to the previous nose
studies, administration of nonviral vectors to the lung
caused mild transient inflammation.30 These finding were
subsequently reproduced in the United States by Ruiz and
colleagues.108 Combined, these studies showed that (a)
gene transfer to the airway epithelium (nose and lung) was
feasible, (b) partial correction of the CFTR-dependent
chloride transport defect, but not the sodium transport
defect, could be achieved in some, but not all, studies, and
(c) administration of nonviral vectors was safe, but the
nose did not predict the mild lung inflammatory responses.
As for all but one of the viral gene therapy trials, all nine
nonviral gene therapy studies published to date were phase
I/IIa safety studies, not designed to assess clinical benefit of
gene therapy. The three U.K. centers involved in CF gene
therapy trials based in London, Oxford, and Edinburgh
formed the U.K. CFGTC in 2002 with the explicit aim to
assess whether gene therapy can improve CF lung disease.
From the start we anticipated that answering this question
will require a long (*12 months), double-blinded, placebo-
controlled multidose trial sufficiently powered to assess
clinical benefit. Since 2002 the U.K. CFGTC has conducted
a phased translational research program (Table 2) and key
stages are described below.
1. Activity in the 1990s led to the development of a myriad of
nonviral gene transfer agents, but it is our impression that
progress in developing novel formulations for airway gene
therapy has been modest and that GL67A, which was used
in the first U.K. nonviral lung trial (see previously) in 1999
remains the most potent nonviral vector for airway gene
transfer more than a decade later.112 We also compared a
range of commercially available nebulizers to select the
most appropriate device for aerosol delivery of pGM169/
GL67A complexes.113
2. The mild inflammatory responses and transient duration
of gene expression noted by Alton and colleagues after
single-dose administration of GL67A/pCFTR aerosols to
the lungs of patients with CF30 led to the development
of CpG-nucleotide free plasmids containing a synthetic
transcriptional regulator consisting of the elongation factor-
1a promoter and the human cytomegalovirus (CMV)
enhancer.114 This novel CpG-free plasmid led to reduced
inflammation by avoiding activation of Toll-like receptor
(TLR)-9 pathways, and prolonged (> 4 weeks) gene ex-
pression in mouse models.
3. A study aimed at selection of putative end-point assays
based on their responses to conventional antibiotic
treatments during an exacerbation (tracking study; see
Table 2) allowed the identification of key biomarkers of
inflammation, imaging, and physiology that alter along-
side symptomatic improvement after treatment of an
acute CF exacerbation. These data, in parallel with our
study of biomarkers in patients with stable CF (run-in
study; see Table 2), provided important guidance in
choosing optimal biomarkers for subsequent gene ther-
apy trials.115
4. After selection of the most potent nonviral gene transfer
agent (pGM169/GL67A) a single-dose phase I/IIa open-
label safety trial was conducted to select the most ap-
propriate dose of pGM169/GL67A for the subsequent
multidose safety trial. This trial included assessment of
molecular efficacy (correction of CFTR-dependent
chloride transport in lungs and nose of treated patients)
(CFGTC manuscript in preparation).
Table 2. U.K. Cystic Fibrosis Gene Therapy Program
Phase Objectives Progression criteria
Preclinical selection and
development of a GTA
suitable for repeated
administration to patients
with CF
Selection of pGM169/GL67A 1. Transfection of AECs
2. Low toxicity
3. Repeat administration feasible
4. Stability in nebulizer
5. GMP production feasible
Tracking study Validation of putative end-point
assays in patients undergoing
exacerbations
Selection of end points that respond
to conventional treatment
Single-dose phase I/IIa
pilot trial
1. Selection of suitable dose for MDT
2. Confirmation of dosing interval
in patients with CF
1. Suitable dose: 5ml of pGM169/
GL67A per dose
2. Dosing interval: Monthly for 12 months
Run-in study 1. Selection of primary and secondary
end points
2. Characterization of most suitable
patient population for MDT trial
1. Primary end point: Percent change
in relative FEV1 from baseline
2. Inclusion of patients > 12 years
and with baseline FEV1 of 50 to 90%
Multidose murine and ovine
regulatory-compliant
toxicology studies
Prove safety in animal models 1. No chronic inflammation
2. No remodeling of lung
3. No extrapulmonary effects
Multidose, double-blinded,
placebo-controlled
phase IIb trial
Significant difference in primary
end point comparing active
and placebo groups
Depending on outcome of trial
AECs, airway epithelial cells; CF, cystic fibrosis; FEV1, forced expiratory volume in the first second; GMP, Good Manufacturing
Process; GTA, gene transfer agent; MDT, multidose trial.
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5. A study aimed at (a) selection of putative end-point assays
based on their sensitivity and variability in stable patients
and at (b) selection of the most appropriate patient pop-
ulation (run-in study; see Table 2) included approximately
200 patients. During trial visits, which were scheduled
approximately every 6 months, patients underwent a range
of assays including a one-off deposition scan. A key factor
for patient selection is to find a good balance between
‘‘can deliver’’ (not too severe to prevent GL67A/pDNA
deposition) and ‘‘can measure’’ (not too well to mask
clinical efficacy).
6. Before progression into a multidose clinical trial, regula-
tory-compliant toxicology studies were performed. Mice
received 12 doses of pGM169/GL67A over 6 months
and sheep received 9 doses of pGM169/GL67 at monthly
intervals.116,117 All animals tolerated the treatment well.
We did not observe any chronic inflammatory responses,
lung remodeling, or any extrapulmonary responses and the
no-observed adverse event limit (NOAEL) supported
progression into a multidose clinical trial.
7. The multidose, double-blinded placebo controlled phase
IIb trial designed to assess clinical efficacy started in
summer 2012 and was completed 2 years later. The trial
included patients 12 years and older with an FEV1
between ‡ 50% to £ 90% predicted. All mutation types
were included, although, as expected, the vast majority of
patients were F508del homo- or compound heterozygotes.
Patients received 12 monthly 5-ml doses of pGM169/
GL67A containing 13.25mg of plasmid DNA complexed
to 75mg of GL67A (or placebo [saline]) by aerosol. The
primary end point was a relative change in percent pre-
dicted FEV1. Secondary outcomes included additional
measurements of lung function, CT scans, and Cystic
Fibrosis Questionnaire-revised (CFQ-R). Exploratory end
points included exercise testing, activity monitoring, and
sputum inflammatory markers. Mechanistic end points
included nasal and/or bronchial vector-specific DNA,
mRNA, and electrophysiological assessment of CFTR
function. Safety was extensively evaluated. Results from
116 patients (54 placebo, 62 active) are being analyzed
and, depending on the outcome, may be either further
assessed in phase III studies or may require further im-
provement in efficacy and consistency of response.
Conclusions
Research into CFTR correctors and, more importantly,
the potentiator Kalydeco, has shown that the molecular
defect of CFTR is drug targetable and that amelioration of
CFTR function translates into improvements in disease
phenotype. These findings have renewed interest and in-
vestment into other therapies aimed at targeting the mo-
lecular defect, including gene therapy. In contrast to the
mutation class–specific treatments described previously,
gene therapy is mutation class independent and will likely
be suitable for all patients. However, proof-of-concept that
gene therapy can improve CF lung disease is currently
lacking and the results of the U.K. CF Gene Therapy Con-
sortium’s nonviral phase IIb trial, which has been com-
pleted, are awaited. Lentiviral vectors hold promise for CF
gene therapy because of their long-lasting expression and
efficacy on repeated administration.
Although not covered in this review, it is also important
to briefly consider genome editing in the context of CF.
Strategies based on zinc finger nucleases, transcription ac-
tivator-like effector nucleases (TALENs), and more recently
CRISPR–Cas9 are widely used to generate in vitro and
in vivo models.118 In the context of CF, Schwank and col-
leagues used the CRISPR–Cas9 technology to correct the
CFTR locus in human and mouse intestinal organoids.119
Similarly, Lee and colleagues used zinc finger nucleases to
correct the F508del mutation in an in vitro model.120
However, genome editing of the CFTR locus is currently
more suited to the development of preclinical models, rather
than of therapeutic value in the context of CF lung therapy.
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